Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Cytomx Thera (CTMX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 954,910
  • Shares Outstanding, K 38,960
  • Annual Sales, $ 71,620 K
  • Annual Income, $ -43,100 K
  • 36-Month Beta 0.92
  • Price/Sales 13.33
  • Price/Cash Flow N/A
  • Price/Book 19.22

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.43 +8.78%
on 06/28/18
25.68 -4.98%
on 06/21/18
-1.28 (-4.98%)
since 06/20/18
3-Month
19.86 +22.86%
on 06/04/18
27.34 -10.75%
on 04/23/18
-2.61 (-9.66%)
since 04/20/18
52-Week
13.09 +86.40%
on 08/03/17
35.00 -30.29%
on 03/08/18
+11.01 (+82.23%)
since 07/20/17

Most Recent Stories

More News
Dow Spends Fifth Day in the Green

Dow Spends Fifth Day in the Green

WERN : 39.35 (+3.28%)
CTMX : 24.40 (-0.45%)
BBY : 76.11 (-2.40%)
VNDA : 20.80 (-0.72%)
CytomX Therapeutics Announces Closing of Public Offering of Common Stock

CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody(TM) therapeutic...

CTMX : 24.40 (-0.45%)
Look for Shares of Cytomx Therapeut to Potentially Rebound after Yesterday's 9.79% Sell Off

Cytomx Therapeut (NASDAQ:CTMX) traded in a range yesterday that spanned from a low of $22.83 to a high of $25.20. Yesterday, the shares fell 9.8%, which took the trading range below the 3-day low of...

CTMX : 24.40 (-0.45%)
CytomX Therapeutics Announces Pricing of Public Offering of Common Stock

CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody(TM) therapeutic...

CTMX : 24.40 (-0.45%)
CytomX Therapeutics Announces Proposed Public Offering of Common Stock

CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody(TM) therapeutic...

CTMX : 24.40 (-0.45%)
Free Technical Research on Edge Therapeutics and Three More Biotech Equities

Stock Research Monitor: CTMX, DVAX, and EDIT

CTMX : 24.40 (-0.45%)
DVAX : 15.75 (+0.64%)
EDIT : 36.25 (+0.33%)
EDGE : 1.00 (-1.96%)
CytomX Announces Appointment of Lloyd A. Rowland Jr. as General Counsel

CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody(TM) therapeutic...

CTMX : 24.40 (-0.45%)
Shares of Cytomx Therapeut Rank the Highest in Terms of Relative Performance in the Biotechnology Industry (CTMX , ENTA , RARE , INSY , AKBA )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

CTMX : 24.40 (-0.45%)
RARE : 82.90 (-1.19%)
ENTA : 122.34 (-0.64%)
CytomX Therapeutics Presents Preliminary Clinical Proof-of-Concept Data from Probody(TM) Platform and CX-072 at 2018 ASCO Annual Meeting

- PD-L1 Targeting Probody CX-072 Well Tolerated and Shows Antitumor Activity as Monotherapy and in Combination with Ipilimumab -

CTMX : 24.40 (-0.45%)
CytomX Announces Conference Call and Webcast to Review PROCLAIM-072 Clinical Data Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody(TM) therapeutic...

CTMX : 24.40 (-0.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade CTMX with:

Business Summary

CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered...

See More

Key Turning Points

2nd Resistance Point 25.07
1st Resistance Point 24.74
Last Price 24.40
1st Support Level 24.19
2nd Support Level 23.97

See More

52-Week High 35.00
Fibonacci 61.8% 26.63
Last Price 24.40
Fibonacci 50% 24.05
Fibonacci 38.2% 21.46
52-Week Low 13.09

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar